These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12183236)

  • 41. Antiviral activity of the EB peptide against zoonotic poxviruses.
    Altmann SE; Brandt CR; Jahrling PB; Blaney JE
    Virol J; 2012 Jan; 9():6. PubMed ID: 22225618
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Skin inflammation in RelB(-/-) mice leads to defective immunity and impaired clearance of vaccinia virus.
    Freyschmidt EJ; Mathias CB; MacArthur DH; Laouar A; Narasimhaswamy M; Weih F; Oettgen HC
    J Allergy Clin Immunol; 2007 Mar; 119(3):671-9. PubMed ID: 17336617
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The adenovirus E3 14.7-kilodalton protein which inhibits cytolysis by tumor necrosis factor increases the virulence of vaccinia virus in a murine pneumonia model.
    Tufariello J; Cho S; Horwitz MS
    J Virol; 1994 Jan; 68(1):453-62. PubMed ID: 8254756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation.
    Scott JE; ElKhal A; Freyschmidt EJ; MacArthur DH; McDonald D; Howell MD; Leung DY; Laouar A; Manjunath N; Bianchi T; Boes M; Oettgen HC; Geha RS
    J Allergy Clin Immunol; 2007 Dec; 120(6):1382-8. PubMed ID: 17889291
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo.
    De Clercq E; Holý A; Rosenberg I
    Antimicrob Agents Chemother; 1989 Feb; 33(2):185-91. PubMed ID: 2719463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role for host-immune factors in the in vivo antiviral effects of tumour necrosis factor.
    Lidbury BA; Ramshaw IA; Sambhi SK
    Cytokine; 1995 Feb; 7(2):157-64. PubMed ID: 7780035
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma.
    Kohonen-Corish MR; King NJ; Woodhams CE; Ramshaw IA
    Eur J Immunol; 1990 Jan; 20(1):157-61. PubMed ID: 2106440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of efficacy of aurintricarboxylic acid and ethacrynic acid against vaccinia virus respiratory infections in mice.
    Smee DF; Hurst BL; Wong MH
    Antivir Chem Chemother; 2010 Apr; 20(5):201-5. PubMed ID: 20413827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of poxvirus infections in rabbits with 9-beta-D-arabinofuranosyladenine.
    Klein RJ; Friedman-Kien AE; Brady E
    Antimicrob Agents Chemother; 1974 Apr; 5(4):409-12. PubMed ID: 15825397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The vaccinia virus kelch-like protein C2L affects calcium-independent adhesion to the extracellular matrix and inflammation in a murine intradermal model.
    Pires de Miranda M; Reading PC; Tscharke DC; Murphy BJ; Smith GL
    J Gen Virol; 2003 Sep; 84(Pt 9):2459-2471. PubMed ID: 12917467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox.
    Adams MM; Rice AD; Moyer RW
    J Virol; 2007 Oct; 81(20):11084-95. PubMed ID: 17686856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative.
    Ikeda S; Yazawa M; Nishimura C
    Antiviral Res; 1987 Oct; 8(3):103-13. PubMed ID: 2827566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.
    Acuna SA; Ottolino-Perry K; Çako B; Tang N; Angarita FA; McCart JA
    Ann Surg Oncol; 2014 Jul; 21(7):2259-66. PubMed ID: 24719018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of fatal disseminated vaccinia virus infection in immunosuppressed mice.
    Worthington M; Conliffe M
    J Gen Virol; 1977 Aug; 36(2):329-333. PubMed ID: 302323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances.
    Smee DF; Bailey KW; Wong MH; Tarbet EB
    Antivir Chem Chemother; 2011 May; 21(5):201-8. PubMed ID: 21566266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lung surfactant DPPG phospholipid inhibits vaccinia virus infection.
    Perino J; Crouzier D; Spehner D; Debouzy JC; Garin D; Crance JM; Favier AL
    Antiviral Res; 2011 Jan; 89(1):89-97. PubMed ID: 21095206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Deletion of the
    Bravo Cruz AG; Han A; Roy EJ; Guzmán AB; Miller RJ; Driskell EA; O'Brien WD; Shisler JL
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490586
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
    Stittelaar KJ; van Amerongen G; Kondova I; Kuiken T; van Lavieren RF; Pistoor FH; Niesters HG; van Doornum G; van der Zeijst BA; Mateo L; Chaplin PJ; Osterhaus AD
    J Virol; 2005 Jun; 79(12):7845-51. PubMed ID: 15919938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
    Stott EJ; Taylor G; Ball LA; Anderson K; Young KK; King AM; Wertz GW
    J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergistic combination effect of cidofovir and idoxuridine on vaccinia virus replication.
    Remichkova M; Petrov N; Galabov AS
    Antivir Chem Chemother; 2006; 17(2):53-8. PubMed ID: 17042327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.